Mulberry Developments acquires GlaxoSmithKline site in Harlow

Mulberry Property Developments (Mulberry Developments) is pleased to announce the successful acquisition of the former GlaxoSmithKline South site in Harlow, Essex. The site extends to 44.6 acres and includes approximately 326,704 sq ft of industrial/R&D space, which has been leased back to GlaxoSmithKline.

With approximately 29 acres available for a new industrial/logistics/data centre development – subject to planning – Mulberry Developments will be preparing the site and seeking new occupiers for the proposed scheme.

Phil Jones, Development Director at Mulberry Developments said: “This is an exciting new acquisition for Mulberry Developments and we look forward to engaging with local occupiers and the community to deliver a successful scheme that contributes to the local economy and potentially create up to 570 new jobs.”

M1 Agency LLP acted on behalf of Mulberry Developments.